Toll-like Receptor-4 Activation Boosts the Immunosuppressive Properties of Tumor Cells-derived Exosomes.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
11 06 2019
11 06 2019
Historique:
received:
22
10
2018
accepted:
24
05
2019
entrez:
13
6
2019
pubmed:
13
6
2019
medline:
21
10
2020
Statut:
epublish
Résumé
The biology of tumor-derived exosomes (TEX) is only partially understood and much remains to be studied in order to define the effect that the tumor microenvironment or the activation of tumor cells exerts on their composition and functions. Increased expression and activity of toll-like receptor 4 (TLR4) in chronic infectious and inflammatory conditions is related with cancer progression: its activation induces an inflammatory signaling that increases the tumorigenic potential of cancer cells promoting their immune evasion. We investigated the immune modulatory properties of TEX released upon cell TLR4 activation, and we found that, although differences were observed depending on the type of the tumor, the treatment influences TEX composition and boosts their immunosuppressive ability. Our results suggest that the activation of TLR4 supports tumor progression by stimulating the release of more effective immunosuppressive exosomes, which allow tumor cells to escape immune surveillance and probably even play a role in the metastatic process.
Identifiants
pubmed: 31186484
doi: 10.1038/s41598-019-44949-y
pii: 10.1038/s41598-019-44949-y
pmc: PMC6560033
doi:
Substances chimiques
Immunosuppressive Agents
0
MicroRNAs
0
TLR4 protein, human
0
Toll-Like Receptor 4
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8457Références
Oncogene. 2014 Jul 3;33(27):3485-95
pubmed: 23934186
Acta Pharmacol Sin. 2018 Apr;39(4):501-513
pubmed: 29219950
Cytokine. 2017 Jan;89:127-135
pubmed: 26854213
Biochim Biophys Acta. 2014 Apr;1845(2):182-201
pubmed: 24440852
Front Immunol. 2015 Jan 29;6:19
pubmed: 25688245
J Immunol. 2008 Jun 1;180(11):7249-58
pubmed: 18490724
J Clin Invest. 2015 Sep;125(9):3347-55
pubmed: 26325032
Front Immunol. 2014 Mar 31;5:135
pubmed: 24744758
Oncoimmunology. 2017 Jul 19;6(8):e1261243
pubmed: 28919985
J Exp Clin Cancer Res. 2016 Jun 27;35:103
pubmed: 27349385
Oncol Res. 2012;20(1):15-24
pubmed: 23035361
Cell Physiol Biochem. 2016;39(5):1665-1678
pubmed: 27639612
Clin Dev Immunol. 2011;2011:609579
pubmed: 22110526
PLoS One. 2017 Jan 20;12(1):e0169932
pubmed: 28107450
Philos Trans R Soc Lond B Biol Sci. 2018 Jan 5;373(1737):
pubmed: 29158311
Vaccines (Basel). 2016 Oct 20;4(4):
pubmed: 27775593
Front Immunol. 2014 Jul 15;5:334
pubmed: 25076949
J Hepatocell Carcinoma. 2015 Feb 16;2:11-7
pubmed: 27508190
Cancer Med. 2018 May;7(5):2013-2020
pubmed: 29601673
Oncol Rep. 2013 Sep;30(3):1249-56
pubmed: 23836405
PLoS One. 2014 Sep 30;9(9):e108925
pubmed: 25268476
Cancer Res. 2015 Jun 15;75(12):2405-10
pubmed: 25998620
Arch Immunol Ther Exp (Warsz). 2017 Aug;65(4):311-323
pubmed: 28101591
Eur Rev Med Pharmacol Sci. 2014;18(24):3834-43
pubmed: 25555874
J Immunol Res. 2014;2014:149185
pubmed: 24901008
Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7312-7
pubmed: 23589885
Cancer Biol Ther. 2012 Jul;13(9):727-36
pubmed: 22617774
Cancer Res. 2007 Aug 1;67(15):7458-66
pubmed: 17671216
Oncotarget. 2014 Jul 30;5(14):5439-52
pubmed: 24978137
Cancer Lett. 2011 Dec 8;311(2):195-202
pubmed: 21852034
Comput Struct Biotechnol J. 2016 Oct 27;15:8-13
pubmed: 27872688
Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):E2110-6
pubmed: 22753494
Am J Cancer Res. 2017 Nov 01;7(11):2199-2208
pubmed: 29218244
Am J Med Sci. 2010 Apr;339(4):319-26
pubmed: 20228668
Adv Clin Chem. 2016;74:103-41
pubmed: 27117662
Semin Cell Dev Biol. 2017 Jul;67:3-10
pubmed: 28077297
Adv Exp Med Biol. 2017;1036:81-89
pubmed: 29275466
Cell Mol Life Sci. 2018 Jan;75(2):193-208
pubmed: 28733901
J Clin Invest. 2016 Apr 1;126(4):1208-15
pubmed: 27035812
J Biol Chem. 2011 Feb 4;286(5):3418-28
pubmed: 21127066
Anat Rec (Hoboken). 2017 Jul;300(7):1219-1229
pubmed: 28296189
Eur J Immunol. 2006 Jun;36(6):1598-607
pubmed: 16708399
PLoS One. 2014 Oct 09;9(10):e109980
pubmed: 25299052
Semin Cancer Biol. 2014 Oct;28:24-30
pubmed: 24602822
J Clin Invest. 2016 Apr 1;126(4):1216-23
pubmed: 26927673
Mediators Inflamm. 2016;2016:6978936
pubmed: 27293318
World J Gastroenterol. 2014 May 21;20(19):5808-17
pubmed: 24914341
Semin Cell Dev Biol. 2015 Apr;40:72-81
pubmed: 25724562
Oncol Rep. 2011 Feb;25(2):503-11
pubmed: 21152870
Sci Rep. 2018 Sep 6;8(1):13325
pubmed: 30190615